Analysis of parasympathetic nerve dysfunction during night in overlap syndrome with obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD)

Analysis of parasympathetic nerve dysfunction during night in overlap syndrome with obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) - Parasympathetic nerve dysfunction in overlap syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023323

Enrollment

400

Registered

2016-07-25

Start date

2016-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overlap syndrome with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD)

Interventions

No therapy for 6 months Continuous positive airway pressure (PAP) treatment only for 6 months Inhaled bronchodilators only for 6 months Continuous positive airway pressure (PAP) treatment + inhaled

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: OSA: age: more than 40 years old, FEV1/FVC: more than 70% after bronchodilator inhalation, and AHI: more than 20 events/hour COPD: age: more than 40 years old, FEV1/FVC: less than 70% after bronchodilator inhalation, and AHI: less than 10 events/hour Overlap syndrome: age: more than 40 years old, FEV1/FVC: less than 70% after bronchodilator inhalation, and AHI: more than 20 events/hour

Exclusion criteria

Exclusion criteria: Central sleep apnea (CSA) predominating over OSA Periodic leg movement disorders Atrial fibrillation, artificial cardiac rhythms by pacemakers, significant ectopic beats Severe systemic diseases, including malignancy in any organ, severe heart failure, heart attack or stroke, renal failure requiring dialysis, and impaired cognitive function

Design outcomes

Primary

Measure	Time frame
Improvement of airflow limitation by continuous PAP therapy in Overlap syndrome	—

Secondary

Measure	Time frame
1) Nighttime parasympathetic nerve activity and stability estimated by instantaneous time-frequency analysis in OSA, COPD, and Overlap syndrome 2) Improvement of nighttime parasympathetic nerve activity and stability by PAP therapy in OSA and Overlap syndrome	—

Countries

Japan

Contacts

Public ContactKazuhiro Yamaguchi

Tokyo Women's Medical University Comprehensive Medical Center of Sleep Disorders

yamaguc@sirius.ocn.ne.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026